Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Anti-CD20 monoclonal antibody

Ublituximab

Brand names: Briumvi

Ublituximab is an anti-CD20 monoclonal antibody given by intravenous infusion as a disease-modifying treatment for relapsing forms of multiple sclerosis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds CD20 on B lymphocytes and produces rapid B-cell depletion, largely through antibody-dependent cellular cytotoxicity, reducing the B-cell-driven inflammation that contributes to relapses and new lesions.

Prescribing in practice

  • Infusion-related reactions are common, so infusions are given with premedication and under observation, particularly with the first dose.
  • B-cell depletion increases infection risk and can cause hypogammaglobulinaemia; hepatitis B status should be checked and vaccinations brought up to date before starting.
  • Live vaccines should be avoided during treatment and the depleted period afterwards.

Monitoring

Monitor for infusion reactions during and after administration, and watch for infections and immunoglobulin levels over the course of treatment.

Counselling the patient

  • Report any fever, persistent cough or other signs of infection.
  • Tell your clinician about any planned vaccinations, as live vaccines must be avoided.

Evidence & guidelines

Its efficacy in relapsing MS, including reduced relapse rates versus an oral comparator, was shown in the ULTIMATE I and II randomised trials.

Reference: NICE TA958; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways